Endeavour Capital Advisors’s Cardlytics CDLX Stock Holding History
Bought
Maintained
Sold
Other funds holding CDLX
CIP
6CM
ACM
KGAMU
JCM
Endeavour Capital Advisors's CDLX Position: Q2 2022 in Review
Endeavour Capital Advisors sold out of Cardlytics (CDLX) in Q2 2022, closing a stake of 7,629 shares — an estimated $4.19M sold.
Endeavour Capital Advisors first reported a position in CDLX in Q2 2021 and held it in 4 quarters. The position peaked at $19.1M in Q2 2021. 138 funds tracked by Wall St. Rank hold CDLX as of Q2 2022.
- Endeavour Capital Advisors reported no remaining Cardlytics position as of Q2 2022 after selling out during the quarter.
- Endeavour Capital Advisors sold 7,629 Cardlytics shares in Q2 2022, an estimated $4.19M.
- Endeavour Capital Advisors first reported a position in Cardlytics in Q2 2021 and held it in 4 quarters.
- Endeavour Capital Advisors's Cardlytics position peaked at $19.1M in Q2 2021.
- 138 funds tracked by Wall St. Rank held Cardlytics as of Q2 2022.
Based on Endeavour Capital Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.